Summary
We previously characterized a receptor of Mr 105,000 for human lactoferrin (hLf) on Jurkat human lymphoblastic T-cells. To delineate the role of R2R3R4R5 of hLf in the interaction with cells, we studied the binding of hLf variants obtained either by tryptic proteolysis (hLf−2N, hLf−3N and hLf−4N)or by mutagenesis (rhLf−5N). Consecutive removal of N-terminal arginine residues from hLf progressively increased the binding affinity but decreased the number of binding sites on the cells. The binding parameters of bovine Lf and native hLf did not differ, whereas the binding parameters of murine Lf resembled those of rhLLf−5N. Culture of Jurkat cells in the presence of chlorate, which inhibits sulfation, reduced the number of binding sites for both native hLf and hLf−3N but not for rhLf−5N indicating that the hLf binding sites include sulfated molecules. The results suggest that the interaction of hLf with about 80,000 binding sites per Jurkat cell, mainly sulfated molecules, is dependent on R2R3R4, but not on R5. Interaction with about 20,000 binding sites per cell, presumably the hLf receptor, does not require the first N-terminal basic cluster of hLf. We conclude that the deletion of R2–R5 from hLf may serve to modulate the nature of its binding to cells and thereby its effects on cellular physiology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mikogami, T., Heyman, M., Spik, G. and Desjeux, J.F. (1994) Am. J. Physiol. 267, G308–G315
Rochard, E., Legrand, D., Lecocq, M., Hammelin, R., Crépin, M., Montreuil, J. and Spik, G. (1992) Anticancer Res. 1, 2047–2052
McAbee, D.D. and Esbensen, K. (1991) J. Biol. Chem. 226, 23624–23631
Ziere, G.J., van Dijk, M.C.M., Bijsterbosch, M.K. and van Berkel, T.J.C. (1992) J. Biol. Chem. 267, 11229–11235
Birgens, H.S., Karle, H., Hansen, N.E. and Kristensen, L. (1984) Scand. J. Haematol. 33, 275–280
Mazurier, J., Legrand, D., Hu, W.L., Montreuil, J. and Spik, G. (1989) Eur. J. Biochem. 179, 481–487
Leveugle, B., Mazurier, J., Legrand, D., Mazurier, C., Montreuil, J. and Spik, G. (1993) Eur. J. Biochem., 213, 1205–1211
Appelmeik, B.J., An, Y.Q., Geerts, M., Thijs, B.G., de Boer, H.A., MacLaren, D.M. de Graaff, J. and Nuijens, J.H. (1994) Infect. Immun. 62, 2628–2632
Elass-Rochard, E., Roseanu, A., Legrand, D., Trif, M., Salmon, V., Motas, C., Montreuil, J. and Spik, G. (1995) Biochem. J. 312, 839–845
Mann, D.M., Romm, E. and Migliorini, M. (1994) J. Biol. Chem. 269, 23661–23667
Wu, H.F., Monroe, D.M. and Church, F.C. (1995) Arch. Biochem. Biophys. 317, 85–92
Hutchens, T.W, Henry, J.F. and Yip, T.T. (1991) Pediatr. Res. 29, 243–250
Jorieux, S., Mazurier, J., Montreuil, J. and Spik, G. (1985) Prot. Biol. Fluids 32, 115–118
van Berkel, P.H.C., Geerts, M.E.J., van Veen, H.A., Mericskay, M., de Boer, H.A. and Nuijens, J.H., (1997) Biochem. J., 328, 145–151
van Berkel, P.H.C., Geerts, M.E., van Veen, N.A., Kooiman, P.M., Pieper, F.R., de Boer, H.A. and Nuijens, J.H. (1995) Biochem. J. 312, 107–114
Metz-Boutigue, M.H., Jollès, J., Mazurier, J., Schoentgen, F., Legrand, D., Spik, G., Montreuil, J. and Jollès, R. (1984) Eur. J. Biochem. 145, 659–676
Rey, M.W., Woloshuk, S.L., de Boer, H.A. and Pieper, F.R. (1990) Nucleic Acids Res. 18, 5288
Pierce, A., Colavizza, D., Benaïssa, M., Maes, P., Tartar, A., Montreuil, J. and Spik, G. (1991) Eur. J. Biochem. 196, 177–184
Pentecost, B.T. and Teng, C.T. (1987) J. Biol. Chem. 262, 10134–10139
Legrand, D., Mazurier, J., Elass, A., Rochard, E., Vergoten, G., Maes, P., Montreuil, J. and Spik, G. (1992) Biochemistry 31, 9243–9251
Zimecki, M., Mazurier, J., Machnicki, M., Wieczorek, Z., Montreuil, J. and Spik, G. (1991) Immun. Lett. 30, 377–382
Ziere, G.J., Kruit, J.K., Bijsterbosch. M.K. and van Berkel, T.J.C. (1993) J. Biol. Chem. 268, 27069–27075
Huettinger, M., Retzek, H., Hermann, M. and Goldenberg, H. (1992) J. Biol. Chem. 267, 18551–18557
Keller, K.M., Brauer, P.R. and Keller, J.M. (1989) Biochemistry 28, 8100–8107
Spik, G., Strecker, G., Fournet, B., Bouquelet, S., Montreuil, J., Dorland, L., van Halbeek, H., Vliegenthart, J.F.G. (1982) Eur. J. Biochem. 121, 413–419
Legrand, D., van Berkel, P.H.C., Salmon, V., van Veen, H.A., Slomianny, M.-C., Nuijens, J.H. and Spik, G. (1997) Biochem. J. 327, 841–846
Salmon, V., Legrand, D., Georges, B., Slomianny, M.-C., Coddeville, B. and Spik, G. (1997) Protein Expression Purif. 9, 203–210
Bi, B.Y., Liu, J.L., Legrand, D., Roche, A.C., Capron, M., Spik, G. and Mazurier, J. (1996) Eur. J. Cell Biol. 69, 288–296
Scatchard, G. (1949) Ann. N.Y. Acad. Sci. 51, 660–672
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Legrand, D. et al. (1998). Role of the First N-Terminal Basic Cluster of Human Lactoferrin (R2R3R4R5) in the Interactions with the Jurkat Human Lymphoblastic T-Cells. In: Spik, G., Legrand, D., Mazurier, J., Pierce, A., Perraudin, JP. (eds) Advances in Lactoferrin Research. Advances in Experimental Medicine and Biology, vol 443. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9068-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9068-9_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9070-2
Online ISBN: 978-1-4757-9068-9
eBook Packages: Springer Book Archive